Capricor Therapeutics shares rise as FDA decision nears
At a glance
- $CAPR today+1.33%last $8.41
- Vs industry peers+2.18 pts6-peer median −0.85% · far ahead
- Since Nov 10−9.57%from the first trade after the story
- 52-week range184.1% above low$2.96 – $40.37
- Cash runway~4 mo$44.3M cash ÷ $10.8M/mo burn · 10-Q
- Coverage2 this week2 in 30 days · too few stories to call a pace
Nothing reported about capricor across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Healthcare gains often hinge on key events like approvals or trial results — not slow, steady progress.
- How the stock is trading: $CAPR +1.33% in the latest session.
- Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
Capricor Therapeutics ($CAPR) rose 1.33% to $8.41 in the latest session. Over the past month it is up 26.5%. That leaves it 79% below its 52-week high of $40.37 and 184% above its low of $2.96. It has been a volatile year: the high was 13.6 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $CAPR lost $42.7M over the quarter to Sep 30, 2026. Operations used $96.4M of cash over the nine months to Sep 30, 2026 — about $10.8M a month — against $44.3M in cash on Sep 30, 2026. At that pace the cash covers about 4 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $120.6M against $44.3M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $CAPR's own account and the first thing to read. Figures are as filed with the SEC; the $CAPR page has the full statements.
How much coverage it is getting
This is one of 2 stories on Capricor Therapeutics in Wook's last 30 days of coverage, including 2 this week. That is well above its usual pace: over the month it has averaged less than one a week. Going by their wording, 1 read bullish, 1 neutral and 0 bearish. This one reads bullish too, in line with most of them. Seeking Alpha wrote 2 of them; the rest came from other outlets.
The bigger picture
In healthcare, a single FDA decision or trial update can shift a drugmaker's fate, while pricing changes ripple across the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $CAPR page includes the full chart, filings, and valuation model. Comparing coverage from different outlets helps spot confirmation or repetition. Wook AI can also crunch the numbers — how far $CAPR has come or how this week's news stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 11, 2026. $CAPR has moved -9.57% ($9.30 to $8.41). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
